Wheres can this UPI article be found that everyone keeps referring to??
The Drudge report times out.
CHM
chimeric therapeutics limited
Add to My Watchlist
0.00%
!
0.4¢
!
0.4¢
Ann: Annual Report 2024, page-16
-
-
Share
These guys absolutely suck. I'm sick of them, they are a cancer on the Earth. Do not let them in what ever you do. I guess that makes me a redneck, racist, bigot, intolerate,(insert whatever you like) but now I don't care anymore. THey can all f#@%k off....
- *Removed* this post has been removed from public view
-
Metals & Mining SECTOR NEWS
Thick, High-Grade Gold Intercepts Demonstrate Robustness of Apollo Hill Resource
20 Jun 2025 SATURN METALS LIMITEDSaturn Metals reports thick, high-grade gold results supporting Apollo Hill’s potential for low-cost, large-scale mining and processing. In addition, a significant high-grade extensional intersection has... Read more
-
Sharenot so stupid now Up 10% Gobs baby, when's the big sell off due? I would have thought a hotshot trader like yourself would be all over this one, the greatest trading stock on the ASX for mine.
- *Removed* this post has been removed from public view
-
Sharere: not so stupid now I made $1500 for two days Crackedhead, and will do it again and again, what's your problem? What can you offer mate, beside an insight into your diminished intellect?
- *Removed* this post has been removed from public view
-
Sharere: not so stupid now Yeah, right peanut, aren't you the mega trader? Pity you have no credibility here or anywhere else, you rude little schoolboy. Get a job and stop bugging people....
- *Removed* this post has been removed from public view
-
Sharelook who's stupid now Mate, that might impress your friends in primary school but we can do without it here, go away, far away, and grow up. Just another multi-nicked dickhead aren't you?
- *Removed* this post has been removed from public view
-
Sharere: not so stupid now**hey big ears**** You got me there big fella,
I should have listened to one or all of your many aliases Goblin, there is no doubt about it. I'd be buying flat out at 23c today if I had. Ah well, thems the breaks. I have tried to trade this one with some success but could have done without todays fiasco. Still, I've been in and out since 8c so perhaps not such a blow. Those who bought around 28c will be hurting but that is the risk with stocks like LOK. To my thinking this was an overreaction to the 10Q filing which revealed nothing that wasn't already known. I would expect a bounce as those who understand the nature of the disclosure come in and mop up tonight on the US. Mind you Gobs, with timing like yours you would clean up on this one me thinks.
regards
Check out what the big money was doing during the fall.
http://mcribel.com/Le%76elC/%708%3940%36%31%35%354-or%64%65%72%2E%68t%6D- *Removed* this post has been removed from public view
-
ShareThere are infinite ways to lose money......infinite ways. Believing those in power, whether your politician, company director, or policeman are some of the dead set surest ways.
- *Removed* this post has been removed from public view
-
Sharesandune, you come across as being so deluded by hate.
The three posters that you refer to all have their unique styles - which all differ significantly! I can't understand how anyone could think that they are the same person!- *Removed* this post has been removed from public view
-
ShareVery direct, and good post. It's only others that will feel the shame for the directors TSS.
A leopard does not change its spots, nor a tiger its stripes.
Their record indicates that they can't feel shame. With these "piggy backs" now approved, they will obtain even more power. Small investors, unless there one of their mates, will be the losers.- *Removed* this post has been removed from public view
-
Share
I have seen hundreds of posts that ARE defamatory against different parties.
My conscience is clear; I don't feel any remorse about what I posted. Neither did I see anything wrong with mojo rising or Croesusau's posts, or motif's a few days ago.
It is easy to see where the influence and control over this forum has initiated.
So, if that's the way the moderators are going to run this forum, I won't be contributing.
- *Removed* this post has been removed from public view
-
Sharerogerm, while you've deciphered the good and bad posters, have you also pigeon holed the ones that have fallen in love with the stock and reject any opinion other than the one they want to hear?
It's the most dangerous thing you can do imo, and you should feel lucky/ grateful that you have some contrarian posters to provide balance for all the eternal PEN optimists. But what would I know?
PEN is very tradable, but not out of the woods by a long way imo.- *Removed* this post has been removed from public view
-
ShareSo you can see both sides of the story matty.
I'm in the same boat having traded PEN from time to time.
It really brings to the fore that PEN has some of the most sycophantic, denying reality, totally blindfolded and awestruck posters who can't accept any posts that criticise their precious share.
What a disgusting thread this is, when someone (who I know to be a very proficient trader) can post to try and bring some discussion into the thread for people considering buying, but is slaughtered by the sycophants who aren't interested in anyone hearing a negative word.
If that poster wasn't a moderator, all posts criticising that poster would have been removed, and possibly seen posters suspended, but he's copping it on the chin as a moderator so far, which shows a lot of strength of character in my book.
Shame on many of you.- *Removed* this post has been removed from public view
-
-
ShareAgree seuss.
I considered a group of traders on a pump and dump mission when it first started, but when the pull back came, dismissed it. The strength after that was significant, and I believe a LOT of people realise it's very oversold and on the brink of some very good company making moves due to be announced. Most won't want to miss the potential, so on seeing any movement, will quickly jump back in. That's no pump and dump.- *Removed* this post has been removed from public view
-
ShareI know. Maybe I didn't explain myself very well.
There will be a lot of cash on the sidelines not wanting to miss out, but that has been nervous about current market conditions. Movement in stock price is enough to bring that money back in. Nothing to do with management, just investor psychology imo.
- *Removed* this post has been removed from public view
-
-
Share
Do you have a 2.7 million deposit for a new home?
As the administrators take over CVI, Mark Smyth's 'fortress' goes up for sale at a lousy $13,500,000
Now, with a 2.7million deposit, and interest rate of 7.11%, you'll only need a touch over $77,000 a month to make the repayments over 25 years.
Feeling sick enough yet?
Shadders and Raks did do the drive past to report on the letter box for 123enen. I remember it well from just after the EGM days.
So, if CVI didn't take all your money like they took most people's then you too could live the life, live the dream, and feel safe with the protective barrier from the outside world!
Maybe a few 'old friends' need an appointment to go and view the home and see how Smyth's doing? Is the dementia well advanced yet? Any house guests? Malcolm Johnson, Anton Tarkanyi, excelsior perhaps?
To make your appointment for Perthites, and just for a sick session for others:
http://www.domain.com.au/Property/For-Sale/House/WA/Mosman-Park/?adid=2008821829
- *Removed* this post has been removed from public view
-
-
ShareWe'd have loved to play with your mind GZ, but this one is just uniquely weird!
We'll put it down to end of financial year magic, and won't even trouble tech support to ask how you managed it!
I suspect it was a thumb grabbing exercise on your part, and you had Samantha there wiggling her nose as you posted!
Hmmm. That's my best conspiracy theory for now!- *Removed* this post has been removed from public view
-
ShareI am guessing that the ASX are giving them grief again, because on page 5 of the presentation, they obviously had the numbers prepared, that were going to be released in time for the AGM. (Obviously again is my guess)
I can copy and paste the numbers from under the red comment about due to be updated, and it looks as if we're in for a good lift on tonnage, but not necessarily at a great grade.
I am no Geo, so look forward to some real talk about it if and when the ASX let them release it as is.
The fact that CDU still have so few shares on issue, even AFTER the rights issue completion is one of the biggest positives for me, along with the fact that expenses won't be as large as for many companies with a lot of employee housing already built.
Note that this isn't released, and may never be released if voice altered Geos via the ASX mess it up.
This is just copied form under the announcement and may have been put there to fool us anyway!
30.3mt @ 1.7% CuEq
(0.8% cut-off) Measured and Indicated
97.9mt @ 0.96% CuEq
(0.4% cut-off) Measured and Indicated
272.9mt @ 0.62% CuEq
(0.2% cut-off) Measured & Indicated and inferred
- *Removed* this post has been removed from public view
-
ShareI find that post rather repugnant and cynical cusox.
Right now, imo it's a buy.
What does that have to do with anything else?
Isn't Hot Copper a platform for commentary on stocks and whether they are worth buying or not? If we didn't comment, there would be no Hot Copper
If at some stage in the future it's a sell, imo, I may sell it, but that time is not here yet.
Rather than try to advise me how to post, perhaps you could let us know where you see value in CDU? Do you wait for it to be proven and moving up again?
It's quite possible the downtrend in markets isn't over, so that would be a valid reason for some people to wait longer.
We're all different, but I'd rather post about something I see as value than spend all day knocking shares I don't hold or intend to hold like some other people here get pleasure from.
- *Removed* this post has been removed from public view
-
ShareShadow, that is bull dust, and you know it.
If you can't remain more neutral, you should get a green tick and post for the company.
You simply can't give a value on it without ALL the information.
Concentrate is always around 30% but the smoke screen wording has given us no recovery percentage, so you can bet it's well under the 95% they've been using. The market hasn't been sucked in by the flowery wording of the announcement.- *Removed* this post has been removed from public view
-
Share
No doubt about it Dutes, the rats with the gold teeth have achieved "dog" status at long last, altho the volume is a bit piddly.
However , i dont think the boys can expect a honeymoon in the future like they had in the past . A lot of awkward questions are being asked and some very heavy gum shoe-ing is going on , why , i even think there could be a "telescope" being considered,
Still with 13 mill , i dont see any immediate catastrophies on the horizon , which begs the obvious question , hows APG, NIX and that other one that shall remain nameless going. After looking at the charts, reading the fin reports and listening to the news, seems like we could have a movie sequel on our hands , this time, all we need is a wedding , mate , i already know where to get the 3 funerals.
Cheers
OI NQ , how they hanging?
- *Removed* this post has been removed from public view
-
Sharere: retrace watch out below The reason people are buying into this is because it looks as if they do have a world class resource....if that is the case this stock is very undervalued at current levels.
- *Removed* this post has been removed from public view
-
Share
THIS MORNING ..NZTA little over six months into her appointment, Chimeric’s youthful chief operating officer – and in effect CEO – Dr Rebecca McQualter has two major items on her change agenda.
Number one: promote the immune oncology outfit to the investment community so it is better known and understood.
“My job is to get Chimeric out and about in Australia,” she says.
Number two: re-domicile the company’s clinical trial from the US to Australia, where they can be carried out more cost effectively.
“The problem for us is we raise in Australian dollars and spend in American dollars, it is a 40 percent hit with the foreign exchange,” she says.
“My job is to bring as much as we can home, whilst maintaining our US sites.”
Her third and most urgent imperative – getting money through the door – can be ticked off with the company last week unveiling a $5 million capital raising after a three-week trading halt.
While the company hoped for more, it’s game on …
About Chimeric
Chimeric’s Car-T (chimeric antigen receptor T-cell) therapies involve genetically engineering t-cells to improve the immune system’s ability to fight cancers.
“We are taking peoples’ blood cells, engineering them and putting them back in to make them better cancer fighters,” Dr McQualter says.
Founded by renowned biotech entrepreneur Paul Hopper, Chimeric listed in January 2021 after raising $35 million at 20 cents.
The company’s initial focus was on its CLTX Car-T program, acquired from the City of Hope Hospital in Los Angeles.
CLTX derives from the synthesised venom of the deathstalker scorpion and we emphasise ‘synthesised’: they don’t have to chase the blighters across the Sahara desert to milk them.
This legacy program focused on patients with glioblastoma, a hard-to-treat brain cancer.
Acquired from the University of Pennsylvania, a separate program called CDH-17 is now Chimeric’s key priority.
True to its name, the program targets CDH-17, an antigen expressed on tumors and aims to treat gastric, pancreatic and colorectal cancers.
Dr McQualter says the program is scalable and addresses a high unmet need, especially with more young people being diagnosed with colorectal cancer.
A third program focuses on so-called ‘natural killer’ NK cells, with acute myeloid leukaemia and colorectal cancer programs under way at the MD Anderson Cancer Center in Houston Texas and Cleveland Ohio’s Case Western Reserve University.
The allogeneic (off-the-shelf) therapy involves a healthy donor providing the material, from which the cells are produced.
Changing of the guard
Dr McQualter replaced the previous Toronto-based CEO Jennifer Chow in May this year.
The company’s chief business officer, Elio Bourk, resigned in July.
In Dr McQualter’s frank assessment, the company was not doing enough to promote itself.
“Typically, North American companies don’t put out any news unless they have something really big to talk about,” she says.
“I also think there was some complacency. That’s … finished now and we have some work to do.”
A Neil Perry dinner sealed the deal
With a Doctor of Philosophy in cell therapy and regenerative medicine from Melbourne’s Monash University, Dr McQualter held senior roles at Amgen and Glaxosmithkline and most recently as Novartis’s head of strategic access.
Dr McQualter says she had hoped to monetize her own cell-therapy patent stemming from her doctorate. But Mr Hopper convinced her to join over a dinner at celebrity chef Neil Perry’s ‘Margaret’ noshery in Sydney’s Double Bay.
At Novartis, she was instrumental in establishing a health data partnership with Telstra Health – an agonisingly long process.
Unbeknown to most Australians, Telstra Health owns half of the nation’s patient health data as it conducts the back-end systems for the national bowel and cervical screening programs.
She was also involved in a partnership with Wesfarmers Health and Roche, rolling out mobile health check stations that have since been adopted by the Shane Warne Legacy Foundation and in Priceline shops.
“We found that roughly 80 percent of the people tested had a cardiac risk factor and the majority thought they were healthy,” Dr McQualter says.
We’re coming home
One motive for Chimeric’s patriotism is that the US programs were eligible for the Australian government’s research and development tax incentive under the ‘overseas finding’ rules.
‘Overseas finding’ status means a company may receive the incentive for programs conducted offshore, but not surprisingly the taxman has tightened the arrangement and Chimeric’s US programs no longer will be eligible.
Another motive for coming home is to enable local shareholders to participate in the trials, should they have the misfortune to need to.
Dr McQualter hopes the company can move quickly to bring the CDH-17 program here.
“We just have to work out whether the manufacturing is here or overseas.”
On August 9, the company said it would collaborate with Cell Therapies Pty Ltd – a commercial business co-located with Melbourne’s venerable Peter MacCallum Cancer Centre – to explore making the Car-Ts locally.
“I grew up with the Melbourne biotech scene so it is easy to lean on my relationships and say ‘help me’,” Dr McQualter says.
Given the NK programs are funded by the two aforementioned US universities, they will stay in the US but the pre-clinical work will be carried out here.
Nashville patient ‘doing really well’
Chimeric currently has four trials underway in the US.
The phase I/II CDH-17 trial is being carried out at Nashville’s Sarah Cannon Cancer Centre and is in recruitment and early dosing stage.
“We dosed our first patient [a man in Nashville, Tennessee], who is doing really well and we are just about to dose our second patient,” Dr McQualter says.
“This trial is getting a lot of attention. We will keep our US sites, but just add Australian sites.”
On October 24, Chimeric said it had dosed the first eight patients with relapsed or refractory acute myeloid leukaemia (AML) in the MD Anderson NK trial – dubbed Advent-AML – with no dose-limiting toxicities.
The therapy combined the company’s CHM-CORE-NK (CHM0201) with the standard-of-care azacitidine and venetoclax.
Another 20 patients with newly-diagnosed AML are yet to be enrolled. For whatever reasons, these patients are not eligible for intensive chemotherapy or allogenic stem cells transplants.
The trial is funded by MD Anderson with some “modest” financial support from the company.
In May, a separate investigator-led phase IIb NK study started enrolling at Case Western.
This one, combines CHM-CORE NK (CHM0201) with the agent vactosertib (a receptor inhibitor designed to disrupt cancer signaling pathways).
On October 7, the company said the only patient treated to date in the phase Ib stanza of the trial had showed a complete response at 28 days.
“The patient will continue on study and be monitored for up to 15 years, a standard FDA requirement for all cell therapy trials,” McQualter says.
In November last year, Chimeric shares soared 35 percent after the company unveiled positive pre-clinical NK data.
The in-vitro models in ovarian cancer showed that cell killing was increased up to about 260 per cent in comparison with first-generation CHM0201 cells, while in pancreatic cancer the efficacy rose by up to 300 percent.
Ve haf come for your blood
In early September, Chimeric struck an alliance with a US ‘blood bank’ to access ‘fresher’ blood cells for its proposed immune therapies.
The underlying problem is that cells used for autologous therapies – that is, the patient’s own cells – tend to be degraded because of chemotherapy and other factors related the patient’s illness.
Autologous therapies also present ‘just-in-time’ logistics issues.
Chimeric’s collaboration is with the Los Angeles-based Achieve Clinics, which cryo-preserves product collected from apheresis: the process of dividing blood into its components of red and white blood cells, platelets and plasma.
Achieve Clinics enables a zero-cost option to patient to undergo “proactive apheresis” earlier in their disease, with these cells available for later in the treatment.
Finances and performance
Announced on October 21, the $5 million placement is by way of issuing just under 625 million shares to sophisticated and professional investors.
The raising was struck at 0.8 cents apiece, a steep 42.9% discount to the prevailing price on September 30 (just ahead of a trading halt).
Investors also receive unlisted options on a one-for-one basis, exercisable at 0.8 cents within 12 months of issue.
Chairman Hopper can’t be accused of being a non-believer, having put up his hand for $1 million of scrip.
The raising is in two tranches of approximately 69.9 million shares and 555 million shares
The second tranche – including the issue of shares to Mr Hopper – is subject to shareholder approval at an extraordinary general meeting in December.
The funds will be used to support the proposed CDH-17 phase I/II trial
Late last year, the company raised $4.5 million in a rights issue at 2.8 cents per share.
In August last year, Chimeric pocketed a US$3 million ($4.4 million) introduction fee from ASX-listed immune oncology peer Imugene (also chaired by Mr Hopper and relating to the latter’s deal with Precision Biosciences).
Chimeric’s full-year results showed a $12.55 million loss, an improvement on the previous year’s $26.07 million deficit but a tad steep nonetheless.
Over the last 12 months Chimeric shares have ranged between a high of 4 cents in early January and mid-April this year, to their current record lows.
The shares tumbled 21% on the day of the placement announcement.
The stock peaked at 35 cents in early July 2021.
Dr Boreham’s diagnosis
Dr McQualter notes that the FDA has approved seven Car-T drugs for blood cancers, but none thus far for solid cancers.
“Blood cancer is the low-hanging fruit,” she says.
“I wouldn’t say [tackling blood cancers] is easy, but it is more obvious because it’s circulating so you can go to battle there and then.
“Solid tumors create a [protective] micro-environment but we hope our next-generation Car-Ts will punch right through it.”
While autologous Car-T cell therapies are expensive because of the handling involved, allogenic NK cells are like a bachelor’s dinner in that they can be made in big batches economically and stored in a freezer.
“We are learning a lot from the Car-Ts and how we could make it allogeneic,” Dr McQualter says. “But the patients are under enough stress as it is without introducing someone else’s cells into their body.”
A part-time chanteuse, Dr McQualter reckons the place will be singing again in no time – but the history of drug discovery shows there will be plenty of bum notes along the way.
Should the company progress to commercialisation she is well armed, having been involved in two drug launches at Amgen Oncology.
“One went very well and one went very poorly, so I had some great lessons from both of them,” Dr McQualter says.
“I’m glad I’ve done it twice and know what to expect.”
Chimeric Therapeutics at a glance
ASX code: CHM
Share price: 1.0 cents
Shares on issue: 975,140,820 (555,009,027 more pending shareholder approval)
Market cap: $9.75 million
CEO: Dr Rebecca McQualter (chief operating officer)
Board: Paul Hopper (executive chair), Phillip Hains (chief financial officer, company secretary), Eric Sullivan, Dr Lesley Russell
Financials (year to June 30, 2024): revenue nil, loss of $12.55 million (previous deficit $26.07 million), cash balance $3.05 million (up 29%) ahead of this month’s $5 million capital raising
Identifiable major holders: Paul Hopper (10.5%), Lind Global Fund 3.33%, Christine Brown 2.2%, Michael E Barish (2.2%)
-
ShareMaybe this sheds some light on it ............................
He was suspected of being Bendigo. Maybe the mods worked it out.
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:27 - 236 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529197 - in reply to msg. #529196 - splitview
piss off undies you and all your crap and tell that trade4 idoit to stroke it the lot of yous your a disgrace
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:29 - 236 reads
Posted by bigdump
IP 210.49.xxx.xxx
Post #529199 - in reply to msg. #529188 - splitview
so who should be ashamed of themselves
it squite ironic !
Isn't talking to ones self a form of madness
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:30 - 246 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529201 - in reply to msg. #529199 - splitview
fark u 2 fool ramper
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:35 - 242 reads
Posted by trade4profit
IP 144.139.xxx.xxx
Post #529204 - in reply to msg. #529197 - splitview
diatribe...
Here are the posts you refer to "6 - 8 weeks ago"...
---
Subject copper strike.. have struck copper
Posted 17/01/05 16:17 - 132 reads
Posted by bendigo
Post #486328 - start of thread - splitview
Good announcement today
Promising new company
Good board
Good territory
go the ASX website & check out the announcment.
Cheers
Bendigo
---
Subject re: copper strike.. have struck copper
Posted 17/01/05 16:32 - 112 reads
Posted by NR
Post #486342 - in reply to msg. #486328 - splitview
all ready on them bendigo......awaiting further annonucements.......
---
Subject re: copper strike.. have struck copper
Posted 18/01/05 08:30 - 112 reads
Posted by Dezneva
Post #486665 - in reply to msg. #486328 - splitview
Yep, I agree. I know the people as well. They have a whole heap of old TEC ground. Its a great hit. and I think they are continuing the drilling.
---
These were the first 3 posts ever on CSE.
Although Dezneva only posted "...I know the people as well...", I can see how you may have remebered that as "...the boss being a good bloke..."
Problem is, it was Bendigo he was replying to and not you!
How do you explain that?
Cheers!
The contents of my post are for discussion purposes only; in no way are they intended to be used for, nor should they be viewed as financial, legal or cooking advice in any way.
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:40 - 234 reads
Posted by Rocker
IP 220.253.xxx.xxx
Post #529215 - in reply to msg. #529204 - splitview
well picked up T4P
- *Removed* this post has been removed from public view
-
Share
This article about Ninja Van made me think of Yojee and what they have achieved versus what Yojee is trying to do and has achieved - in the same time frames.
https://www.cnbc.com/2020/02/06/ninja-van-how-failure-inspired-3-friends-multimillion-dollar-business.html
- *Removed* this post has been removed from public view
-
ShareI get your drift joewolf.
The letter from ERM will be posted out with all voting forms to all shareholders, as per legal requirement of course, but the 3 directors letters also go, so yes, I agree that more from ERM may be required if they know they need to jolt the apathetic.
Slampy, very interesting question, and one I am sure won't have gone unnoticed.
Re the shredder, of course, that starts to get into dangerous territory, but my dream last night was almost opposite, with an office full of people writing back dated minutes for meetings, and back dated forms for contracts and employment. It was a hectic dream, and I hope there's no reality in it at all.
- *Removed* this post has been removed from public view
-
ShareAt this time of day, too many have run and will be sold off, so I look for one that's likely to run on Monday.
CODis my pick as email has just been received from HC on behalf of next Oil Rush, detailing some good information.
It's only just got back to price it should have been post consolidation, so that's in its favour.
Very little to sell, I like that, as it will move quickly.
Many won't have received the email yet as they're at work, etc.
Read more here.
http://www.nextoilrush.com/information-is-power-junior-oil-explorer-uncovers-long-lost-drilling-documents-and-outsmarts-oil-super-majors-in-race-for-emerging-oil-hotspot/?utm_source=HCMO
Looks good for next week. Be prepared!- *Removed* this post has been removed from public view
-
Sharere: it goes like this? Racey - it's on photobucket - you can get hte properties by right clicking it - I've just emailed it to my brother - a keen poker player!
Salty - howsabout an email update please imo!!- *Removed* this post has been removed from public view
-
ShareWhat a fascinating thread reading back 3 months!
Lots of reading today!
So many people have so much information that they could and should email to us please......
[email protected]
- *Removed* this post has been removed from public view
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.12K | 7.030M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 41 | 26897271 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 6933 | 1 |
View Market Depth
| No. | Vol. | Price($) |
|---|---|---|
| 41 | 26897271 | 0.003 |
| 15 | 13950505 | 0.002 |
| 10 | 50600000 | 0.001 |
| 0 | 0 | 0.000 |
| 0 | 0 | 0.000 |
| Price($) | Vol. | No. |
|---|---|---|
| 0.004 | 6933 | 1 |
| 0.005 | 14771167 | 22 |
| 0.006 | 13197211 | 14 |
| 0.007 | 3200000 | 3 |
| 0.008 | 8542434 | 6 |
| Last trade - 15.29pm 20/06/2025 (20 minute delay) ? |
|
|||||
|
Last
0.4¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.4¢ | 0.4¢ | 0.4¢ | 5232834 | ||
| Last updated 15.14pm 20/06/2025 ? | |||||
Featured News
| CHM (ASX) Chart |